Prevalent cases of OA increased to 527.81 million in 20191 worldwide.
Osteoarthritis is the single most common cause of disability in older adults. Osteoarthritis (OA) is a long-term chronic disease characterized by the deterioration of cartilage in joints which results in bones rubbing together and creating stiffness, pain and impaired movement. The disease most commonly affects the joints in the knees, hands, feet and spine and is relatively common in shoulder and hip joints. While OA is related to aging, it is also associated with a variety of risk factors, such as obesity, lack of exercise, occupational injury and trauma. Through various strategies spanning from physical therapy to medical devices, from drugs to surgery, the treatment of OA aims to relieve pain and improve function.
*The RICHPLAT ORTHO™ Platelet Rich Plasma System is designed to be used for the safe and rapid preparation of autologous platelet rich plasma (PRP) from a small sample of peripheral blood at the patient’s point of care. The PRP is mixed with autograft and/or allograft bone prior to application to a bony defect for improving handling characteristics.
Fidia Pharma USA Inc. has a broad family of hyaluronic acid (HA) viscosupplement brands that meet both physician injection frequency and patient access needs in the treatment of osteoarthritis (OA) knee pain.